Loading...
Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
The TRIBE trial compared the FOLFOXIRI regimen plus bevacizumab with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. FOLFOXIRI plus bevacizumab is an acceptable therapeutic option, but the results of the TRIBE trial do not establish this regimen as the best treatment option f...
Na minha lista:
| Udgivet i: | Oncologist |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AlphaMed Press
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4350810/ https://ncbi.nlm.nih.gov/pubmed/25660156 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0495 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|